Skip to main content
. 2018 Apr 13;9(28):19817–19825. doi: 10.18632/oncotarget.24865

Figure 2. Progression-free survival, survival time after progression, and the response of individual patients who received oxaliplatin-based chemotherapy.

Figure 2